Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotechnologies Raises $6.4M to Support FDA Submission

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced the closing of a financing round that raised $6.4 million.

The funding includes $4 million in new capital and the conversion of $2.4 million in outstanding notes into preferred stock, the Pittsfield, Mass.-based firm said.

In August GenomeWeb Daily News reported the company had closed on a Series B round that raised $4.7 million. The $6.4 million reported today includes the earlier amount, a company spokesman said.

The funding will be used to support regulatory approval of its fatty acid synthase assay, including clinical trials, as well as facility upgrades, new hires, and general operations. Nuclea CEO Patrick Muraca said in August that the company planned to submit its fatty acid synthase assay for approval from the US Food and Drug Administration by the end of September.

It is unclear whether the company has yet made its submission.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.